UBS Group’s Rapport Therapeutics RAPP Stock Holding History

UBS Group’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.75M	Sell	151,758 -74,602	-33%	-$2.1M	﹤0.01%	4131
2025 Q4	$6.87M	Sell	226,360 -331,713	-59%	-$9.18M	﹤0.01%	3706
2025 Q3	$16.6M	Buy	558,073 +284,566	+104%	+$5.08M	﹤0.01%	2769
2025 Q2	$3.11M	Buy	273,507 +208,760	+322%	+$2.22M	﹤0.01%	4357
2025 Q1	$649K	Buy	64,747 +43,419	+204%	+$564K	﹤0.01%	5645
2024 Q4	$378K	Buy	21,328 +15,771	+284%	+$349K	﹤0.01%	6036
2024 Q3	$114K	Buy	5,557 +2,430	+78%	+$52.2K	﹤0.01%	6259
2024 Q2	$72.7K	Buy	+3,127	New	+$72.4K	﹤0.01%	6399

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

UBS Group's RAPP Position: Q1 2026 in Review

UBS Group reduced its Rapport Therapeutics (RAPP) stake by 33% in Q1 2026, selling an estimated $2.1M and leaving 151,758 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4131.

UBS Group first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $16.6M in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

UBS Group held 151,758 shares of Rapport Therapeutics worth $4.75M as of Q1 2026.
UBS Group sold 74,602 Rapport Therapeutics shares in Q1 2026, an estimated $2.1M.
Rapport Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4131 holding.
UBS Group first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
UBS Group's Rapport Therapeutics position peaked at $16.6M in Q3 2025.
147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.